WO2009031230A1 - 抗ｃｄ２０モノクローナル抗体 - Google Patents

抗ｃｄ２０モノクローナル抗体 Download PDF

Info

Publication number
WO2009031230A1
WO2009031230A1 PCT/JP2007/067444 JP2007067444W WO2009031230A1 WO 2009031230 A1 WO2009031230 A1 WO 2009031230A1 JP 2007067444 W JP2007067444 W JP 2007067444W WO 2009031230 A1 WO2009031230 A1 WO 2009031230A1
Authority
WO
WIPO (PCT)
Prior art keywords
human
monoclonal antibody
monoclonal antibodies
antigen
animal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2007/067444
Other languages
English (en)
French (fr)
Inventor
Susumu Uchiyama
Kiichi Fukui
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Osaka NUC
Original Assignee
Osaka University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osaka University NUC filed Critical Osaka University NUC
Priority to JP2009531068A priority Critical patent/JPWO2009031230A1/ja
Priority to PCT/JP2007/067444 priority patent/WO2009031230A1/ja
Priority to EP07806885A priority patent/EP2186892A1/en
Priority to CN200780101422A priority patent/CN101848999A/zh
Priority to US12/674,783 priority patent/US20110263825A1/en
Publication of WO2009031230A1 publication Critical patent/WO2009031230A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

　ヒトＣＤ２０抗原を発現しているヒトＢ細胞株と、ヒトＣＤ２０のＤＮＡで形質転換された非ヒトかつ被免疫動物とは異なる動物由来の細胞株とを免疫原とするヒトＣＤ２０抗原を有する細胞に対する増殖阻害活性を有するモノクローナル抗体、及びこれをキメラ化又はヒト化したモノクローナル抗体を提供する。本発明のモノクローナル抗体は、医薬として好適な生物学的活性を示す。
PCT/JP2007/067444 2007-09-06 2007-09-06 抗ｃｄ２０モノクローナル抗体 Ceased WO2009031230A1 (ja)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2009531068A JPWO2009031230A1 (ja) 2007-09-06 2007-09-06 抗ｃｄ２０モノクローナル抗体
PCT/JP2007/067444 WO2009031230A1 (ja) 2007-09-06 2007-09-06 抗ｃｄ２０モノクローナル抗体
EP07806885A EP2186892A1 (en) 2007-09-06 2007-09-06 Anti-cd20 monoclonal antibodies
CN200780101422A CN101848999A (zh) 2007-09-06 2007-09-06 抗-cd20单克隆抗体
US12/674,783 US20110263825A1 (en) 2007-09-06 2007-09-06 Anti-cd20 monoclonal antibodies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2007/067444 WO2009031230A1 (ja) 2007-09-06 2007-09-06 抗ｃｄ２０モノクローナル抗体

Publications (1)

Publication Number Publication Date
WO2009031230A1 true WO2009031230A1 (ja) 2009-03-12

Family

ID=40428553

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/067444 Ceased WO2009031230A1 (ja) 2007-09-06 2007-09-06 抗ｃｄ２０モノクローナル抗体

Country Status (5)

Country Link
US (1) US20110263825A1 (ja)
EP (1) EP2186892A1 (ja)
JP (1) JPWO2009031230A1 (ja)
CN (1) CN101848999A (ja)
WO (1) WO2009031230A1 (ja)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011113308A1 (zh) 2010-03-17 2011-09-22 永卓博济(上海)生物医药技术有限公司 一种新型人源化抗cd20单克隆抗体
JP2016512489A (ja) * 2013-02-26 2016-04-28 ロシュ グリクアート アーゲー 抗ｍｃｓｐ抗体
WO2016196344A1 (en) 2015-05-30 2016-12-08 Molecular Templates, Inc. De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
US9758591B2 (en) 2012-08-24 2017-09-12 The Regents Of The University Of California Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
US10688181B2 (en) 2016-06-27 2020-06-23 The Regents Of The University Of California Cancer treatment combinations

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10610104B2 (en) 2016-12-07 2020-04-07 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
US20210138213A1 (en) 2017-03-30 2021-05-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
US20220249814A1 (en) 2018-11-19 2022-08-11 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04502408A (ja) * 1988-12-28 1992-05-07 プロテイン　デザイン　ラブス，インコーポレイティド ＩＬ―２レセプターのｐ５５　Ｔａｃタンパク質に特異的なキメラ免疫グロブリン

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04502408A (ja) * 1988-12-28 1992-05-07 プロテイン　デザイン　ラブス，インコーポレイティド ＩＬ―２レセプターのｐ５５　Ｔａｃタンパク質に特異的なキメラ免疫グロブリン

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HONG K. ET AL.: "Simple quantitative live cell and anti-idiotypic antibody based ELISA for humanized antibody directed to cell surface protein CD 20.", J.IMMUNOL. METHODS., vol. 294, no. 1-2, 2004, pages 189 - 197, XP004679767 *
PRESTA LG. ET AL.: "Humanization of an anti- vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders.", CANCER RES., vol. 57, no. 20, 1997, pages 4593 - 4599, XP055354366 *
YOSHIYA TANAKA: "Ko CD 20 Kotai", JAPANESE JOURNAL OF CLINICAL MEDICINE, vol. 63, no. 5, 2005, pages 728 - 733, XP008132095 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011113308A1 (zh) 2010-03-17 2011-09-22 永卓博济(上海)生物医药技术有限公司 一种新型人源化抗cd20单克隆抗体
US9758591B2 (en) 2012-08-24 2017-09-12 The Regents Of The University Of California Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
US10344096B2 (en) 2012-08-24 2019-07-09 The Regents Of The University Of California Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
US11312787B2 (en) 2012-08-24 2022-04-26 The Regents Of The University Of California Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
US12162950B2 (en) 2012-08-24 2024-12-10 The Regents Of The University Of California Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
JP2016512489A (ja) * 2013-02-26 2016-04-28 ロシュ グリクアート アーゲー 抗ｍｃｓｐ抗体
WO2016196344A1 (en) 2015-05-30 2016-12-08 Molecular Templates, Inc. De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
EP3636660A1 (en) 2015-05-30 2020-04-15 Molecular Templates, Inc. De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
EP3660035A1 (en) 2015-05-30 2020-06-03 Molecular Templates, Inc. De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
US10688181B2 (en) 2016-06-27 2020-06-23 The Regents Of The University Of California Cancer treatment combinations
US11654193B2 (en) 2016-06-27 2023-05-23 The Regents Of The University Of California Cancer treatment combinations

Also Published As

Publication number Publication date
EP2186892A1 (en) 2010-05-19
US20110263825A1 (en) 2011-10-27
JPWO2009031230A1 (ja) 2010-12-09
CN101848999A (zh) 2010-09-29

Similar Documents

Publication Publication Date Title
WO2009031230A1 (ja) 抗ｃｄ２０モノクローナル抗体
WO2011050106A3 (en) Anti-cd3 antibody dosing in autoimmune disease
EP4371570A3 (en) Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b
CL2007003479A1 (es) Anticuerpo monoclonal humano anti-cd22 o un fragmento de union a antigeno del mismo; acido nucleico, vector, celula huesped; método de preparacion; composicion; inmunoconjugado; y su uso para inhibir el crecimiento de un tumor o tratar un desorden inflamatorio o autoinmune en un sujeto.
IL197459A0 (en) Humanized proteins, including antibodies and methods for producing the same
WO2009128963A3 (en) Cross-neutralizing human monoclonal antibodies to sars-cov and methods of use thereof
WO2005103081A3 (en) Human monoclonal antibodies against cd20
UA101487C2 (en) Humanized b-ly1 antibody formulation
WO2011147982A3 (en) Monoclonal antibodies against her2 epitope
WO2016081746A3 (en) Antibodies comprising modified heavy constant regions
EA030777B9 (ru) Анти-альфа-синуклеинсвязывающие молекулы
EP2143795A3 (en) Anti-CD20 monoclonal antibody
EP2517557A3 (en) Animal models and therapeutic molecules
WO2006117699A3 (en) Transgenic animals and methods of making recombinant antibodies
WO2006089231A3 (en) Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues
AR052284A1 (es) Variantes de un anticuerpo y usos de las mismas
WO2011069019A3 (en) J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen
IL184733A0 (en) Human monoclonal antibodies to prostate specific membrane
IL202102A0 (en) Use of a monoclonal, chimeric humanized or human antibody that binds il-5r in the manufacture of a medicament for reducing eosinophil levels
NZ600262A (en) Anti-her3 antibodies and uses thereof
WO2008069999A3 (en) Anti-p-selectin antibodies and methods of using the same to treat inflammatory diseases
WO2007027805A3 (en) Method for generating anti-variable region monoclonal antibodies
EP2000541A4 (en) HUMANIZED MONOCLONAL ANTI-CD20 ANTIBODY
MX341958B (es) Anticuerpos contra el il33r humano y usos de los mismos.
WO2007110678A3 (en) Neutralizing antibodies and methods of use thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780101422.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07806885

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 12674783

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2007806885

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009531068

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE